|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.08 CHF | +0.19% |
|
+2.49% | +20.72% |
| Dec. 05 | Novartis raises guidance and target price after strong execution |  |
| Dec. 04 | Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- NOVN Stock
- Consensus Novartis AG
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
